

# APTUS PHARMA LIMITED

---

Date: 12.06.2026

To,  
The BSE Ltd  
Phiroze Jeejeebhoy Tower,  
Dalal Street,  
Mumbai – 400001

SECURITY CODE: 544529  
SCRIPT SYMBOL: APPL

Dear Sir / Madam,

**Subject: Outcome of the Meeting of the Board of Directors held on 12th June, 2026 — pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations").**

With reference to our prior intimation letter dated **09th June, 2026** filed pursuant to Regulation 29(1)(d) of the SEBI LODR Regulations, and in continuation thereof, we hereby inform you that the **Meeting of the Board of Directors of Aptus Pharma Limited** (hereinafter referred to as "the Company") was duly held on **Friday, 12th June, 2026**, commencing at **4:00 p.m.** and concluding at **05.30 p.m.** at the corporate office of the Company situated Shri 1st Floor Opp. Satyasai Heart Hospital, Narayan Nagar Kalawad Road, Kankot, Rajkot, Gujarat, India, 360005

## **I. Outcome of the Board Meeting:**

Pursuant to Regulation 30 the Board of Directors, at the aforesaid meeting, has, *inter alia*, considered, deliberated upon and approved the following:

### **Approval of Proposal for Fund Raising for expansion of business operation:**

The Board of Directors of the Company has, subject to the receipt of necessary approvals, including approval of shareholders and other regulatory/statutory approvals as may be applicable, approved a proposal for raising of funds aggregating up to ₹51,00,00,000/- (Rupees Fifty-One Crores only) for expansion of the business operations of the Company, by way of the following:

- a. Preferential Allotment of securities up to an aggregate amount of ₹35,00,00,000/- (Rupees Thirty-Five Crores only);
- b. Debt Finance / Borrowings up to an aggregate amount of ₹10,00,00,000/- (Rupees Ten Crores only); and
- c. Internal Accruals aggregating to ₹6,00,00,000/- (Rupees Six Crores only).

---

**Regd. Address:** Ashutosh Buildcon, Opp. Slok – 2, Nr. Harikrupa Logistic Park, Aslali, Daskroi,  
Ahmedabad, Gujarat – 382427, India

Contact: 76004 27827, E-mail: aptuspharma@rediffmail.com, Website: www.aptus-pharma.com

CIN: U24230GJ2010PLC061957, GSTIN: 24AAICA7890D1ZM

# APTUS PHARMA LIMITED

---

The proposed preferential allotment shall be undertaken in accordance with the applicable provisions of the Companies Act, 2013 and the applicable provisions of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, and shall be subject to such approvals as may be required.

The detailed terms and conditions of the proposed fund raising, including the nature of securities, identified investors, issue price, and other relevant details, to the extent applicable, shall be determined by the Board / Committee thereof in due course and disclosed in accordance with applicable laws.

## **Delegation of Authority to Managing Director:**

The Board of Directors has **authorized and delegated authority** to **Mr. Tejas Hathi, Managing Director**, to undertake the following activities in connection with the Proposed Preferential Allotment referred to in Resolution No. 1 above:

(a) to identify, evaluate, conduct due diligence on, and interact / negotiate with prospective investor(s) / proposed allottee(s), whether from the promoter / promoter group or the non-promoter / public category, in respect of the Proposed Preferential Allotment;

(b) to finalize the names, categories, and details of the proposed allottee(s) in accordance with the eligibility criteria prescribed under Chapter V of the SEBI ICDR Regulations and all other applicable provisions;

(c) to collect and compile all requisite information, declarations and documents from the proposed allottee(s) as may be required under the Companies Act, 2013, the SEBI ICDR Regulations, and other applicable laws; and

(d) to place before the Board of Directors, at a subsequent meeting convened for the purpose, a comprehensive report containing the finalized list of proposed allottees(s), along with all statutory particulars and required details, for consideration and approval of the Board of Directors.

It is hereby clarified that the aforesaid delegation of authority is limited to identification, evaluation, interaction, and finalization for the purpose of placing the matter before the Board of Directors. The **final approval** of the Proposed Preferential Allotment, including the determination of the issue price, the number of securities to be issued, the identity of allottee(s), the record date, and the approval of the notice of EGM / AGM, shall be considered and approved by the **Board of Directors at a subsequent meeting** in accordance with applicable laws.

## **II. Important Note — Stage of Transaction**

It is hereby clarified and brought to the notice of the Exchange and the investing public that:

---

**Regd. Address:** Ashutosh Buildcon, Opp. Slok – 2, Nr. Harikrupa Logistic Park, Aslali, Daskroi,  
Ahmedabad, Gujarat – 382427, India

Contact: 76004 27827, E-mail: aptuspharma@rediffmail.com, Website: www.aptus-pharma.com

CIN: U24230GJ2010PLC061957, GSTIN: 24AAICA7890D1ZM

# APTUS PHARMA LIMITED

---

(a) The resolutions passed at the aforesaid Board Meeting are **enabling / in-principle resolutions** establishing the maximum ceiling for fund raising and delegating identification authority to the Managing Director.

(b) The specific details of the Proposed Preferential Allotment, including but not limited to the **issue price, number of securities, identity and category of proposed allottees, relevant date, record date**, and all other material particulars as required under the SEBI ICDR Regulations and the SEBI LODR Regulations, **have not been finalized / approved** at this stage and shall be deliberated upon and approved by the Board of Directors at a **subsequent Board Meeting**, after which a separate and comprehensive disclosure shall be made to the Exchange in accordance with Regulation 30 of the SEBI LODR Regulations.


(c) The approval of the shareholders of the Company by way of a **Special Resolution** at the EGM / AGM, and such other regulatory approvals as may be required, shall be obtained before giving effect to the Proposed Preferential Allotment.

The aforesaid information is also being simultaneously hosted on the website of the Company at [www.apthuspharma.com](http://www.apthuspharma.com).

Kindly take the above on record.

Thanking You,

Yours faithfully,  
For Aptus Pharma Limited



**Tejash Hathi**  
**Managing Director**  
**DIN: 03151221**

---

**Regd. Address:** Ashutosh Buildcon, Opp. Slok – 2, Nr. Harikrupa Logistic Park, Aslali, Daskroi,  
Ahmedabad, Gujarat – 382427, India

Contact: 76004 27827, E-mail: [aptuspharma@rediffmail.com](mailto:aptuspharma@rediffmail.com), Website: [www.apthus-pharma.com](http://www.apthus-pharma.com)

CIN: U24230GJ2010PLC061957, GSTIN: 24AAICA7890D1ZM